Frances Rylands-Monk[email protected]ConferenceBI-RADS 3 arouses controversy, poses management challengesFor breast lesions, BI-RADS 3 allows the possibility of a "wait and see" approach instead of immediate biopsy. Given the growing number of incidental benign findings during screening and clinical breast imaging, this can be a key benefit. But the category also poses management challenges.March 3, 2011ConferenceUncertainty remains over MRI's clinical role in breast imagingMRI can be of value for detecting cancer recurrence in the treated breast, but it continues to arouse controversy when it comes to other indications. Radiologists need to understand the indications for breast MRI and be aware of its advantages and limitations, especially in high-risk cases.March 3, 2011Previous PagePage 41 of 41Top StoriesCTJFR: Radiologists, urologists, and patients collaborate for kidney tumor treatmentMinimally-invasive thermoablation techniques and software are evolving rapidly with a view to improving reproducibility and tolerability of procedures.Partner ContentBayer’s Joana Reis: Breast screening moves beyond one-size-fits-allPartner ContentBehind the scan: From warehouse to patient in MaastrichtIndustry NewsSopris Capital buys Blackford Analysis from BayerAIneuroRAD video: Joe Lennerz on continuous evidence tracking in medical AI